Harrow

Harrow’s foundation is built on a commitment to patient access and affordable medications. Our promise – of access and affordability – serves as a guiding principle in how we execute our strategy. Learn More at Harrow.com #Harrow #Ophthalmology #Optometry

The Harrow Family, our people, are our greatest asset. Together, we’re fiercely devoted to making a difference in ophthalmology. Our goal is to provide eyecare professionals with the innovative products they need to preserve the priceless gift of sight for their patients. As our CEO Mark L. Baum often says, “The number one 'leading indicator' of future commercial success for a pharmaceutical company is where the highest impact salespeople are working.” At Harrow, we’re bringing in the best of the best! Dawn Galvez, Vice President of Commercial Operations, and David Scisciani, Vice President of Strategic Accounts, are two new members of the Harrow Family. Their expertise and passion will help propel Harrow toward even greater heights. And they are just the beginning—our team is growing stronger by the day. Together, we are transforming Harrow into a leading ophthalmic pharmaceutical company in North America. Welcome to all the new faces at Harrow! We’re thrilled to have you join us on this incredible journey. #Harrow #Growth #Teamwork #Innovation #Leadership #Ophthalmology #Hiring #IHEEZO #VEVYE #TRIESENCE www.iheezo.com www.vevye.com www.triesencehcp.com

Harrow’s commitment has always been, and will always be, to help patients manage the preservation of their sight by providing access to innovative and affordable medicines. Learn More at Harrow.com #Harrow #Ophthalmology #Optometry

Harrow supports eyecare professionals by providing a broad portfolio of sight-preserving medications used by millions of patients annually. Learn More at Harrow.com #Harrow #Ophthalmology #Optometry

Harrow is a growing leader in the U.S. ophthalmic market. Our amazing journey has taken us from humble beginnings in 2014, when we first began commercial operations with our compounding pharmacy, to our current position with one of the largest ophthalmic product portfolios. Learn More at Harrow.com #Harrow #Ophthalmology #Optometry

Discover the ST difference and offer your patients affordable access through the Harrow Savings Card! Find out more about TobraDex® ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% at www.tobradexst.com TobraDex® ST is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or risk of bacterial ocular infection exists. TobraDex® ST is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. It is also contraindicated in patients with known hypersensitivity to any components of the medication. See safety information and full PI by visiting https://lnkd.in/ep38vKQu Hashtags: #TobraDexST #Harrow

The Harrow team continues to execute on its strategic plan and its mission to help eyecare professionals manage the preservation of their patients' sight by providing access to innovative and affordable medicines. #Harrow #eyecare #TRIESENCE #ophthalmology #retinaphysicians https://lnkd.in/eaduS3Rr

Planning to attend the AOA 2024 Conference in Nashville, TN? Come visit us at booth #1133 to learn more about Harrow and our product offerings. #harrow #AOA2024 #optometry #visitus

Great interview by the team at Healio with Global Ophthalmology Industry Leader and Harrow Board Member Adrienne Graves. https://lnkd.in/e-42yxNv

Discover Why ST Matters. Find out more about TobraDex® ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% at www.tobradexst.com #TobraDexST #Harrow TobraDex® ST is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or risk of bacterial ocular infection exists. TobraDex® ST is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. It is also contraindicated in patients with known hypersensitivity to any components of the medication. See safety information and full PI by visiting https://lnkd.in/ep38vKQu